Correlation of Circulating Acid-Labile Subunit Levels with Insulin Sensitivity and Serum LDL Cholesterol in Patients with Type 2 Diabetes: Findings from a Prospective Study with Rosiglitazone

Table 2

Changes in metabolic parameters after 24 weeks of treatment.

	12 weeks	24 weeks	𝑃
𝑁
Placebo group	29	28
RSG group	28	28
Body weight (kg)
Placebo group	−0.34±1.33	−0.41±1.21	<0.001
RSG group	1.12±1.71	2.98±2.09
BMI (kg/m^2)
Placebo group	−0.13±0.53	−0.16±0.51	<0.001
RSG group	0.45±0.73	1.21±0.88
Systolic blood pressure, mmHg
Placebo group	−10.7±15.3	−8.6±18.8	0.083
RSG group	−0.4±14.4	1.1±11.7
Diastolic blood pressure, mmHg
Placebo group	−1.6±9.4	−3.0±8.3	0.901
RSG group	−1.2±8.0	−0.6±7.0
HbA1c (%)
Placebo group	−0.31±1.43	−0.26±1.37	<0.001
RSG group	−0.55±1.08	−1.16±1.09
Fasting plasma glucose, mmol/L
Placebo group	0.14±3.25	0.75±3.20	<0.001
RSG group	−1.47±2.27	−1.42±2.08
Fasting plasma insulin, pmol/L
Placebo group	−8.53±29.11	−23.30±36.67	0.505
RSG group	−19.96±34.80	−10.79±40.21
Total cholesterol, mmol/L
Placebo group	0.26±0.85	0.20±0.68	<0.001
RSG group	0.91±1.01	0.85±0.81
Total triglyceride, mmol/L
Placebo group	−0.28±1.28	−0.22±1.72	0.822
RSG group	−0.16±1.10	−0.07±0.60
LDLc, mmol/L
Placebo group	0.32±1.03	0.31±0.89	<0.001
RSG group	0.82±0.97	0.86±0.88
HDLc, mmol/L
Placebo group	0.05±0.22	−0.005±0.205	0.566
RSG group	0.08±0.24	−0.006±0.379
HOMA2-%S
Placebo group	6.92±35.76	16.67±22.60	0.533
RSG group	18.57±15.48	11.40±30.26
HOMA2-%B
Placebo group	−10.59±29.84	−17.56±36.40	0.011
RSG group	0.17±42.02	2.58±46.74
HOMA-IR
Placebo group	−0.19±2.27	−0.99±2.64	0.197
RSG group	−1.86±2.28	−1.34±2.40
HOMA-𝛽
Placebo group	−16.27±43.80	−26.40±52.02	0.211
RSG group	−7.79±69.26	−5.61±77.65
Acid-labile subunit, mU/mL
Placebo group	21.99±447.11	19.84±395.67	0.627
RSG group	−88.17±534.27	−117.16±591.92

Each value represents the mean ± standard deviation (𝑛). 𝑃 values represent the between-group comparisons of the changes in the 12- and 24-week values from the baseline value. RSG: rosiglitazone; BMI: body mass index; HbA1c: hemoglobin A1c; LDLc: low-density lipoprotein cholesterol; HDLc: high-density lipoprotein cholesterol; HOMA2-%S: homeostatic model assessment version 2 insulin sensitivity; HOMA2-%B: homeostatic model assessment version 2 𝛽-cell function; HOMA-IR: homeostatic model assessment of insulin resistance; HOMA-𝛽: homeostatic model assessment of 𝛽-cell function.